Skip to main content
. 2015 Jun 17;6(3):289–302. doi: 10.1007/s13300-015-0117-z

Fig. 3.

Fig. 3

Effects of canagliflozin on FPG (LOCF). CANA canagliflozin, FPG fasting plasma glucose, LOCF last observation carried forward, LS least squares, PBO placebo, SE standard error, wk week. Asterisk Not statistically significant vs PBO based on the hypothesis testing sequence (nominal P < 0.001)